Properties (61)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemical compound
|
| gptkbp:affiliatedWith |
gptkb:XYZ_University
gptkb:ABC_Research_Institute |
| gptkbp:analyzes |
gptkb:Dr._Jane_Doe
|
| gptkbp:author |
gptkb:Dr._John_Smith
|
| gptkbp:chemicalFormula |
thiazole derivatives
C20H24N2O2 contains thiazole ring |
| gptkbp:clinicalTrials |
gptkb:United_States
gptkb:schizophrenia Phase III demonstrated efficacy in trials |
| gptkbp:collaborations |
international collaboration
|
| gptkbp:community_service |
primary clinical endpoints met
|
| gptkbp:compatibleWith |
moderate bioavailability
|
| gptkbp:complications |
weight gain
|
| gptkbp:composedOf |
chemical synthesis
|
| gptkbp:dissolved |
soluble in DMSO
|
| gptkbp:dosageForm |
tablet form
once daily dosing |
| gptkbp:drugInterdiction |
IND-123456
may interact with antidepressants |
| gptkbp:enrollment |
diverse patient demographics
adults with schizophrenia |
| gptkbp:fauna |
rat model
|
| gptkbp:funding |
government grant
|
| gptkbp:healthcare |
high patient adherence
|
| https://www.w3.org/2000/01/rdf-schema#label |
WPC-943
|
| gptkbp:impact |
6 months
drowsiness unknown long-term effects |
| gptkbp:is_studied_in |
randomized controlled trial
|
| gptkbp:isATypeOf |
123456-78-9
|
| gptkbp:issueDate |
oral
|
| gptkbp:lifespan |
12 hours
|
| gptkbp:market |
not yet marketed
|
| gptkbp:number_of_stages |
Phase II
|
| gptkbp:nutritionalValue |
liver metabolism
|
| gptkbp:operational_status |
clinical trials
|
| gptkbp:origin |
(2S)-2-(4-(4-(dimethylamino)phenyl)-1,3-thiazol-2-yl)-1-(4-fluorophenyl)ethyl)-1,3-benzothiazole-6-carboxylic acid
|
| gptkbp:patentStatus |
patented
|
| gptkbp:placeOfDeath |
compared to placebo
|
| gptkbp:publications |
published_in_Journal_of_Psychiatry
|
| gptkbp:regulatoryBody |
high affinity for D2 receptors
|
| gptkbp:regulatoryCompliance |
pending approval
|
| gptkbp:related_to |
WPC-944
|
| gptkbp:releaseYear |
2010
2015 |
| gptkbp:research |
positive research findings
|
| gptkbp:research_areas |
neuroscience
psychiatry |
| gptkbp:researchAndDevelopment |
reduced symptoms of schizophrenia
|
| gptkbp:route |
urinary excretion
|
| gptkbp:safety_features |
generally well tolerated
|
| gptkbp:safetyFeatures |
ongoing safety monitoring
|
| gptkbp:sponsor |
gptkb:XYZ_Pharmaceuticals
|
| gptkbp:targets |
gptkb:Dopamine_receptor_D2
|
| gptkbp:technology |
further research needed
|
| gptkbp:triggerType |
Dopamine receptor antagonist
|
| gptkbp:uses |
antipsychotic medication
|
| gptkbp:weight |
324.42 g/mol
|